- Joined
- 27 June 2010
- Posts
- 4,182
- Reactions
- 316
Broadvector Limited (BDV) is developing therapies for the treatment of two diseases associated with ageing: early stage prostate cancer and aseptic loosening of prosthetic implants such as artificial hips. In both cases, the new treatment is based upon gene directed enzyme-prodrug therapy ('GDEPT'), a modern strategy that eliminates a target tissue without the need for highly invasive surgery. GDEPT is a sophisticated site-specific drug delivery system that enables drugs of high potency to be made available to target tissues, without having to circulate through the body first.
http://www.broadvector.com
http://www.broadvector.com